Biotech sector slips amid reported return of ousted FDA official
Source: SeekingAlpha
2025-08-11 06:25:01 ET
More on Sarepta Therapeutics, Capricor Therapeutics, Inc., etc.
- Replimune Group: The Prospects For FDA Approval After Rejection
- Sarepta Therapeutics: Beaten Down, But Not Out
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Capricor rises as FDA meeting renews hopes for rejected cell therapy
- Sarepta Therapeutics Q2 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Biotech sector slips amid reported return of ousted FDA official
Direxion Daily Healthcare Bull 3X Shares
NASDAQ: CURE
CURE Trading
-0.97% G/L:
$99.29 Last:
23,745 Volume:
$100.08 Open:
